AstraZeneca Stock Price, News & Analysis (NYSE:AZN)

$35.94 0.50 (1.41 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$35.94
Today's Range$35.62 - $35.95
52-Week Range$26.51 - $35.95
Volume2.28 million shs
Average Volume3.18 million shs
Market Capitalization$89.95 billion
P/E Ratio25.67
Dividend Yield3.91%
Beta0.76

About AstraZeneca (NYSE:AZN)

AstraZeneca logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:AZN
CUSIPN/A
Phone+44-20-73045000

Debt

Debt-to-Equity Ratio1.09%
Current Ratio0.94%
Quick Ratio0.72%

Price-To-Earnings

Trailing P/E Ratio25.6714285714286
Forward P/E Ratio18.92
P/E Growth2.62

Sales & Book Value

Annual Sales$23.00 billion
Price / Sales3.96
Cash Flow$3.13 per share
Price / Cash11.48
Book Value$6.59 per share
Price / Book5.45

Profitability

Trailing EPS$1.40
Net Income$3.50 billion
Net Margins15.90%
Return on Equity34.02%
Return on Assets8.37%

Miscellaneous

Employees59,700
Outstanding Shares2,532,440,000

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a None dividend on Friday, July 28th. Stockholders of record on Friday, August 11th will be paid a dividend of $0.44 per share on Monday, September 11th. This represents a dividend yield of 2.98%. The ex-dividend date is Wednesday, August 9th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca's stock split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) announced its quarterly earnings data on Thursday, November, 9th. The company reported $1.12 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.57 by $0.55. The business earned $6.23 billion during the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 EPS. View AstraZeneca's Earnings History.

When will AstraZeneca make its next earnings announcement?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, February, 2nd 2018. View Earnings Estimates for AstraZeneca.

Where is AstraZeneca's stock going? Where will AstraZeneca's stock price be in 2018?

19 Wall Street analysts have issued 12 month price objectives for AstraZeneca's stock. Their forecasts range from $35.00 to $39.00. On average, they expect AstraZeneca's share price to reach $37.00 in the next year. View Analyst Ratings for AstraZeneca.

Are investors shorting AstraZeneca?

AstraZeneca saw a decline in short interest in December. As of December 15th, there was short interest totalling 8,687,524 shares, a decline of 35.1% from the November 30th total of 13,393,297 shares. Based on an average daily volume of 3,174,072 shares, the days-to-cover ratio is currently 2.7 days.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer (Age 57)
  • Marc Dunoyer, Executive Director, Chief Financial Officer (Age 64)
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology (Age 45)
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

Who owns AstraZeneca stock?

AstraZeneca's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (0.02%), Bank of Montreal Can (0.02%), Oliver Luxxe Assets LLC (0.00%), Fulton Bank N.A. (0.00%), First Bank & Trust (0.00%) and BLB&B Advisors LLC (0.00%). View Institutional Ownership Trends for AstraZeneca.

Who sold AstraZeneca stock? Who is selling AstraZeneca stock?

AstraZeneca's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, New England Research & Management Inc., Oliver Luxxe Assets LLC and Gofen & Glossberg LLC IL. View Insider Buying and Selling for AstraZeneca.

Who bought AstraZeneca stock? Who is buying AstraZeneca stock?

AstraZeneca's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fulton Bank N.A., BLB&B Advisors LLC, Ingalls & Snyder LLC, First Bank & Trust, Private Trust Co. NA, Bremer Trust National Association and Atria Investments LLC. View Insider Buying and Selling for AstraZeneca.

How do I buy AstraZeneca stock?

Shares of AstraZeneca can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AstraZeneca stock can currently be purchased for approximately $35.94.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $89.95 billion and generates $23.00 billion in revenue each year. The company earns $3.50 billion in net income (profit) each year or $1.40 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The company can be reached via phone at +44-20-73045000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  489 (Vote Outperform)
Underperform Votes:  864 (Vote Underperform)
Total Votes:  1,353
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AstraZeneca (NYSE:AZN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.582.562.542.50
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $37.00$36.60$37.40$38.46
Price Target Upside: 5.50% upside10.08% upside8.02% upside18.73% upside

AstraZeneca (NYSE:AZN) Consensus Price Target History

Price Target History for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018Leerink SwannReiterated RatingMkt Perform -> Market Perform$33.00 -> $36.00LowView Rating Details
1/10/2018BMO Capital MarketsSet Price TargetBuy$38.00LowView Rating Details
12/29/2017JPMorgan Chase & Co.UpgradeNeutral -> OverweightLowView Rating Details
10/18/2017CitigroupUpgradeBuyN/AView Rating Details
10/17/2017CowenReiterated RatingHold$37.00N/AView Rating Details
10/16/2017Credit Suisse GroupUpgradeNeutral -> OutperformN/AView Rating Details
9/25/2017BNP ParibasUpgradeNeutral -> OutperformMediumView Rating Details
9/22/2017Sanford C. BernsteinReiterated RatingMkt Perform -> BuyLowView Rating Details
9/14/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
9/6/2017NatixisUpgradeNeutral -> BuyLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$35.00LowView Rating Details
8/9/2017InvestecUpgradeHold -> BuyLowView Rating Details
8/9/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
8/1/2017Pareto SecuritiesUpgradeSell -> HoldLowView Rating Details
7/28/2017Morgan StanleyDowngradeOverweight -> Equal WeightHighView Rating Details
7/13/2017Goldman Sachs GroupReiterated RatingSellHighView Rating Details
7/13/2017BarclaysReiterated RatingOverweightHighView Rating Details
4/10/2017Jefferies GroupReiterated RatingBuy -> HoldLowView Rating Details
2/21/2017Berenberg BankReiterated RatingBuyN/AView Rating Details
11/11/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/AView Rating Details
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
11/10/2016Bank of AmericaReiterated RatingBuy$41.37N/AView Rating Details
11/10/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
2/28/2016Drexel HamiltonInitiated CoverageBuyN/AView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickN/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart

Earnings by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE AZN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/2/2018$0.44N/AView Earnings Details
11/9/2017Q3$0.57$1.12$6.00 billion$6.23 billionViewN/AView Earnings Details
7/27/20176/30/2017$0.41$0.87$5.04 billion$5.05 billionViewN/AView Earnings Details
4/27/20173/31/2017$0.38$0.99$5.40 billion$5.41 billionViewN/AView Earnings Details
2/2/2017Q416$0.51$1.21$5.43 billion$5.59 billionViewListenView Earnings Details
11/10/2016Q316$0.48$1.32$5.95 billion$5.70 billionViewN/AView Earnings Details
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$0.52$1.21$6.02 billion$5.84 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details
4/29/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
4/27/2011Q1 2011$1.02$1.04ViewN/AView Earnings Details
1/27/2011Q4 2010$0.67$0.68ViewN/AView Earnings Details
10/27/2010Q3 2010$0.76$0.54ViewN/AView Earnings Details
7/30/2010Q2 2010$0.80$0.73ViewN/AView Earnings Details
4/29/2010Q1 2010$0.86$1.02ViewN/AView Earnings Details
10/29/2009Q3 2009$0.68$0.73ViewN/AView Earnings Details
7/30/2009Q2 2009$0.68$0.82ViewN/AView Earnings Details
1/29/2009Q4 2008$0.59$0.63ViewN/AView Earnings Details
4/24/2008Q1 2008$0.60$0.52ViewN/AView Earnings Details
1/31/2008Q4 2007$0.50$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AstraZeneca (NYSE:AZN) Earnings Estimates

Current Year EPS Consensus Estimate: $1.9 EPS
Next Year EPS Consensus Estimate: $1.72 EPS

Dividends

AstraZeneca (NYSE:AZN) Dividend Information

Most Recent Dividend:9/11/2017
Annual Dividend:$1.37
Dividend Yield:3.81%
Dividend Growth:-21.20% (3 Year Average)
Payout Ratio:97.86% (Trailing 12 Months of Earnings)
72.11% (Based on This Year's Estimates)
79.65% (Based on Next Year's Estimates)
Dividend Payments by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2017None$0.442.98%8/9/20178/11/20179/11/2017
2/3/2017semiannual$0.956.81%2/15/20172/17/20173/20/2017
7/29/2016$0.448/10/20168/12/20169/12/2016
2/5/2016$0.932/17/20162/19/20163/21/2016
2/10/2015semiannual$1.905.57%2/18/20152/20/20153/23/2015
8/1/2014semiannual$0.902.48%8/13/20148/15/20149/15/2014
2/10/2014special$1.902.79%2/19/20142/21/20143/24/2014
8/2/2013semiannual$0.903.52%8/14/20138/16/20139/16/2013
2/1/2013special$1.903.72%2/13/20132/15/20133/18/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AstraZeneca (NYSE AZN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

AstraZeneca (NYSE AZN) News Headlines

Source:
DateHeadline
AstraZeneca (AZN) Upgraded at Zacks Investment ResearchAstraZeneca (AZN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 22 at 2:56 PM
Leerink Swann Equities Analysts Increase Earnings Estimates for AstraZeneca plc (AZN)Leerink Swann Equities Analysts Increase Earnings Estimates for AstraZeneca plc (AZN)
www.americanbankingnews.com - January 22 at 2:24 PM
AstraZeneca plc Forecasted to Earn FY2022 Earnings of $3.15 Per Share (AZN)AstraZeneca plc Forecasted to Earn FY2022 Earnings of $3.15 Per Share (AZN)
www.americanbankingnews.com - January 19 at 11:24 PM
AstraZeneca plc (AZN) Given Consensus Rating of "Hold" by AnalystsAstraZeneca plc (AZN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 19 at 7:36 PM
AstraZeneca (AZN) Receives Market Perform Rating from Leerink SwannAstraZeneca (AZN) Receives Market Perform Rating from Leerink Swann
www.americanbankingnews.com - January 19 at 12:12 AM
Why This Biotech Stock Could Outperform Expectations In Lung CancerWhy This Biotech Stock Could Outperform Expectations In Lung Cancer
finance.yahoo.com - January 18 at 12:45 PM
Analysts Issue Forecasts for AstraZeneca plcs FY2017 Earnings (AZN)Analysts Issue Forecasts for AstraZeneca plc's FY2017 Earnings (AZN)
www.americanbankingnews.com - January 18 at 7:20 AM
FY2018 EPS Estimates for AstraZeneca plc Decreased by Analyst (AZN)FY2018 EPS Estimates for AstraZeneca plc Decreased by Analyst (AZN)
www.americanbankingnews.com - January 17 at 7:08 PM
AstraZeneca's Lynparza Label Now Includes Breast CancerAstraZeneca's Lynparza Label Now Includes Breast Cancer
finance.yahoo.com - January 15 at 11:12 AM
Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EUForeign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU
finance.yahoo.com - January 15 at 11:12 AM
$5.76 Billion in Sales Expected for AstraZeneca plc (AZN) This Quarter$5.76 Billion in Sales Expected for AstraZeneca plc (AZN) This Quarter
www.americanbankingnews.com - January 13 at 7:50 AM
US OKs 1st drug aimed at women with inherited breast cancerUS OKs 1st drug aimed at women with inherited breast cancer
marketbeat.com - January 12 at 1:39 PM
U.S. FDA approves expanded use of AstraZeneca cancer drugU.S. FDA approves expanded use of AstraZeneca cancer drug
finance.yahoo.com - January 12 at 11:24 AM
Zacks: Brokerages Expect AstraZeneca plc (AZN) to Announce $0.42 Earnings Per ShareZacks: Brokerages Expect AstraZeneca plc (AZN) to Announce $0.42 Earnings Per Share
www.americanbankingnews.com - January 11 at 5:24 PM
AstraZenecas Asthma Drug Benralizumab Gets Approval in EUAstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
finance.yahoo.com - January 11 at 12:04 PM
AstraZeneca plc (AZN) Short Interest Down 35.1% in DecemberAstraZeneca plc (AZN) Short Interest Down 35.1% in December
www.americanbankingnews.com - January 3 at 4:04 AM
Biotech Dives After Analyst Slashes Expectations For Cancer DrugBiotech Dives After Analyst Slashes Expectations For Cancer Drug
finance.yahoo.com - January 2 at 3:48 PM
4 Large-Cap Pharma Stocks That Outperformed the S&P This Year4 Large-Cap Pharma Stocks That Outperformed the S&P This Year
finance.yahoo.com - December 29 at 3:34 PM
AstraZeneca (AZN) Rating Increased to Buy at JPMorgan Chase & Co.AstraZeneca (AZN) Rating Increased to Buy at JPMorgan Chase & Co.
www.americanbankingnews.com - December 29 at 7:20 AM
AstraZeneca plc (AZN) Expected to Announce Quarterly Sales of $5.76 BillionAstraZeneca plc (AZN) Expected to Announce Quarterly Sales of $5.76 Billion
www.americanbankingnews.com - December 28 at 9:36 PM
Zacks: Analysts Anticipate AstraZeneca plc (AZN) Will Post Earnings of $0.44 Per ShareZacks: Analysts Anticipate AstraZeneca plc (AZN) Will Post Earnings of $0.44 Per Share
www.americanbankingnews.com - December 26 at 3:44 AM
AstraZeneca plc (AZN) Receives Average Recommendation of "Hold" from AnalystsAstraZeneca plc (AZN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 25 at 6:30 PM
Head-To-Head Review: AstraZeneca (AZN) & Amphastar Pharmaceuticals (AMPH)Head-To-Head Review: AstraZeneca (AZN) & Amphastar Pharmaceuticals (AMPH)
www.americanbankingnews.com - December 24 at 3:30 PM
How Did AstraZeneca’s Respiratory Drug Symbicort Perform in 2017?How Did AstraZeneca’s Respiratory Drug Symbicort Perform in 2017?
finance.yahoo.com - December 22 at 11:40 AM
How AstraZeneca’s Respiratory Products Performed in 3Q17How AstraZeneca’s Respiratory Products Performed in 3Q17
finance.yahoo.com - December 22 at 11:40 AM
How AstraZeneca’s Duaklir and Bevespi Performed in 2017How AstraZeneca’s Duaklir and Bevespi Performed in 2017
finance.yahoo.com - December 22 at 11:40 AM
How AstraZeneca’s CVMD Products Performed in 3Q17How AstraZeneca’s CVMD Products Performed in 3Q17
finance.yahoo.com - December 22 at 11:40 AM
How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017
finance.yahoo.com - December 22 at 11:40 AM
AstraZeneca’s Brilinta and Farxiga Posted High Growth in 3Q17AstraZeneca’s Brilinta and Farxiga Posted High Growth in 3Q17
finance.yahoo.com - December 21 at 11:29 AM
How AstraZeneca’s Revenues Trended in 3Q17How AstraZeneca’s Revenues Trended in 3Q17
finance.yahoo.com - December 21 at 11:29 AM
AstraZeneca’s Anti-Diabetes Drugs Onglyza and Bydureon in 2017AstraZeneca’s Anti-Diabetes Drugs Onglyza and Bydureon in 2017
finance.yahoo.com - December 21 at 11:29 AM
How AstraZeneca’s Business Segments Performed in 3Q17How AstraZeneca’s Business Segments Performed in 3Q17
finance.yahoo.com - December 21 at 11:29 AM
AstraZeneca’s CVMD Drugs: Crestor, Seloken, and Atacand after 3Q17AstraZeneca’s CVMD Drugs: Crestor, Seloken, and Atacand after 3Q17
finance.yahoo.com - December 21 at 11:29 AM
US FDA Updates SYMBICORT Label with LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related OutcomesUS FDA Updates SYMBICORT Label with LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related Outcomes
finance.yahoo.com - December 21 at 11:29 AM
A Look at AstraZeneca’s Iressa, Zoladex, Casodex, and ArimidexA Look at AstraZeneca’s Iressa, Zoladex, Casodex, and Arimidex
finance.yahoo.com - December 20 at 11:22 AM
An Overview of AstraZeneca’s Oncology Drug Faslodex after 3Q17An Overview of AstraZeneca’s Oncology Drug Faslodex after 3Q17
finance.yahoo.com - December 20 at 11:22 AM
A Look at AstraZeneca’s Imfinzi Position after 3Q17A Look at AstraZeneca’s Imfinzi Position after 3Q17
finance.yahoo.com - December 20 at 11:22 AM
Chembio Diagnostics (CEMI) and AstraZeneca (AZN) Report Agreement to Develop Point-of-Care Diagnostic Test - StreetInsider.comChembio Diagnostics (CEMI) and AstraZeneca (AZN) Report Agreement to Develop Point-of-Care Diagnostic Test - StreetInsider.com
www.streetinsider.com - December 19 at 3:34 PM
AstraZeneca’s Tagrisso Witnessed High Growth in 3Q17AstraZeneca’s Tagrisso Witnessed High Growth in 3Q17
finance.yahoo.com - December 19 at 11:28 AM
How Is AstraZeneca’s Lynparza Positioned after 3Q17?How Is AstraZeneca’s Lynparza Positioned after 3Q17?
finance.yahoo.com - December 19 at 11:28 AM
AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDAAstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA
finance.yahoo.com - December 19 at 11:28 AM
A Neil Woodford recovery stock I’d buy alongside AstraZeneca plcA Neil Woodford recovery stock I’d buy alongside AstraZeneca plc
uk.finance.yahoo.com - December 18 at 3:33 PM
AstraZeneca: FDA accepts Tagrisso reviewAstraZeneca: FDA accepts Tagrisso review
www.marketwatch.com - December 18 at 11:39 AM
US FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung CancerUS FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer
finance.yahoo.com - December 18 at 11:39 AM
AstraZeneca’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia TrialsAstraZeneca’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials
finance.yahoo.com - December 12 at 11:40 AM
ETFs with exposure to AstraZeneca Plc : December 11, 2017ETFs with exposure to AstraZeneca Plc : December 11, 2017
finance.yahoo.com - December 11 at 3:33 PM
AstraZeneca's COPD Drug Succeeds in Label Expansion StudyAstraZeneca's COPD Drug Succeeds in Label Expansion Study
finance.yahoo.com - December 5 at 11:48 AM
AstraZeneca’s (AZN) Solid Earnings Visibility Keep it a BuyAstraZeneca’s (AZN) Solid Earnings Visibility Keep it a Buy
investorplace.com - December 1 at 4:30 PM
Astrazeneca PLC (AZN) Receives Consensus Rating of "Hold" from AnalystsAstrazeneca PLC (AZN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 30 at 7:48 PM
Celebrity Trainer and Author Bob Harper Teams up with AstraZeneca to Connect with Fellow Heart Attack SurvivorsCelebrity Trainer and Author Bob Harper Teams up with AstraZeneca to Connect with Fellow Heart Attack Survivors
finance.yahoo.com - November 30 at 11:41 AM

SEC Filings

AstraZeneca (NYSE:AZN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AstraZeneca (NYSE AZN) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.